HEMOTEQ
LIVE

Serial Number

76326915

Owner

Hemoteq GmbH

Attorney

Gregory Turocy

Filing Date

Oct 18, 2001

Add to watchlist:

No watchlists yet
View on USPTO

HEMOTEQ Trademark

Serial Number: 76326915 • Registration: 2931143

HEMOTEQ is a trademark filed by Hemoteq GmbH on October 18, 2001. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Hemoteq GmbH (2 trademarks)

Adenauerstrasse 15
52146 Wurseten , DE

Entity Type: 03

HEMOTEQ AG (2 trademarks)

ADENAUERSTRASSE 15
WUERSELEN 52146 , DE

Entity Type: 03

Trademark Details

Filing Date

October 18, 2001

Registration Date

March 8, 2005

Published for Opposition

April 6, 2004

Goods & Services

Commissioned coating services of artificial surgical implants and of surgical implants comprised of living tissue and organs with biopolymers, especially with heparin, heparin derivatives and anti-thrombotic and/or coagulative macromolecular substances * all coating services exclusive of the use of antibodies *

[ heparin preparations and heparin derivatives combined with organic macromolecular substances with anti-thrombotic and/or anti-coagulative properties for use in coating artificial and natural surfaces for intracorporeal and extracorporeal circulation and for use in coating surgical implants; surgical implants comprising living tissue and organs, namely, heats, heart parts, lungs, arteries, veins, aortas of mammals, especially hearts of pigs, heart valves of pigs and corpse veins; surgical implants comprising living tissue and organs coated with heparin, heparin derivatives and macromolecular agents, namely, hearts, heart valves, lungs, arteries, veins and aortas of mammals * all goods exclusive of the use of antibodies * ]

[ surgical implants comprising artificial material, namely, artificial heart valves, hearts, lungs, arteries, veins and aortas; medical instruments and accessories for use with the transfer and handling of blood, namely, tubing, valves, containers, plastic bags, cans, needles, catheters and for use with artificial surgical implants for the cardiovascular system and for extracorporeal circulation; surgical implants comprising artificial material; anti-thrombotic and/or anti-coagulative surgical implants, artificial surfaces, namely, artificial surfaces, namely, artificial heart valves, artificial hearts, artificial lungs, artificial arteries, artificial veins, artificial aortas, tubing, valves, containers, plastic bags, cans, needles, catheters, and accessories for use with the transfer and handling of blood for medical purposes, especially for intracorporeal and extracorporeal circulation; artificial surgical implants coated with heparin, heparin derivatives and macromolecular agents, namely, artificial heart valves, hearts, lungs, arteries, veins and aortas; medical instruments and accessories for use with the transfer and handling of blood coated with heparin, heparin derivatives and macromolecular agents, namely, tubing, valves, containers, plastic bags, cans, needles, catheters and for use with artificial surgical implants for the cardiovascular system and for extracorporeal circulation * all goods exclusive of the use of antibodies * ]

commissioned research and development services in the fields of surrogates for blood and blood substitutes, blood products, blood-compatible materials and blood-compatible implants; commissioned research and development and consultation services in the fields of artificial surgical implants and of surgical implants comprised of living tissue and organs for the cardiovascular system and for extracorporeal circulation, especially coatings with heparin, heparin derivatives and anti-thrombotic and/or anti-coagulative macromolecular substances; biochemical, pharmaceutical, medical and scientific research services in the fields of surrogates for blood, blood substitutes, blood products, blood-compatible material, blood-compatible implants and blood-compatible parts for the cardiovascular system and for extracorporeal circulation * all research and development services exclusive of the use of antibodies *

Filing History

NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Feb 5, 2025 NA89
REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS)
Feb 5, 2025 RNL2
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Feb 5, 2025 89AG
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Feb 5, 2025 APRE
TEAS SECTION 8 & 9 RECEIVED
Oct 11, 2024 E89R
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Mar 8, 2024 REM2
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 12, 2018 TCCA
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Apr 25, 2015 NA89
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Apr 25, 2015 RNL1
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Apr 25, 2015 89AG
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Mar 23, 2015 APRE
TEAS SECTION 8 & 9 RECEIVED
Mar 6, 2015 E89R
CANCELLATION TERMINATED NO. 999999
Jul 14, 2011 CANT
CANCELLATION DENIED NO. 999999
Jul 14, 2011 CAND
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Mar 31, 2011 C15P
AMENDMENT UNDER SECTION 7 - PROCESSED
Mar 31, 2011 A7OK
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Mar 31, 2011 APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Mar 18, 2011 APRE
TEAS SECTION 8 & 15 RECEIVED
Mar 4, 2011 E815
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Apr 21, 2010 ASGN
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
Mar 23, 2010 EROP
POST REGISTRATION ACTION MAILED - SEC. 7
Feb 25, 2010 PRAM
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Feb 24, 2010 APRE
TEAS SECTION 7 REQUEST RECEIVED
Feb 23, 2010 ES7R
CANCELLATION INSTITUTED NO. 999999
Feb 2, 2009 PETC
REGISTERED-PRINCIPAL REGISTER
Mar 8, 2005 R.PR
LAW OFFICE REGISTRATION REVIEW COMPLETED
Oct 22, 2004 REGV
ASSIGNED TO LIE
Oct 19, 2004 ALIE
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Oct 13, 2004 CNPR
ASSIGNED TO EXAMINER
Oct 13, 2004 DOCK
STATEMENT OF USE PROCESSING COMPLETE
Oct 8, 2004 SUPC
USE AMENDMENT FILED
Sep 24, 2004 IUAF
TEAS STATEMENT OF USE RECEIVED
Sep 24, 2004 EISU
NOA MAILED - SOU REQUIRED FROM APPLICANT
Jun 29, 2004 NOAM
PUBLISHED FOR OPPOSITION
Apr 6, 2004 PUBO
EMAIL RECEIVED
Apr 5, 2004 EMRV
NOTICE OF PUBLICATION
Mar 17, 2004 NPUB
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 16, 2004 TCCA
SEC. 44(D) CLAIM DELETED
Feb 4, 2004 44DD
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 7, 2004 CNSA
LETTER OF SUSPENSION MAILED
Nov 19, 2003 CNSL
ASSIGNED TO EXAMINER
Nov 18, 2003 DOCK
PETITION TO DIRECTOR RECEIVED
Oct 29, 2003 PCRC
PAPER RECEIVED
Oct 29, 2003 MAIL
CASE FILE IN TICRS
Oct 18, 2003 CFIT
CASE FILE IN TICRS
Oct 16, 2003 CFIT
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 22, 2003 CRFA
PAPER RECEIVED
Sep 22, 2003 MAIL
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 17, 2003 CRFA
INQUIRY AS TO SUSPENSION MAILED
Mar 19, 2003 CNSI
LETTER OF SUSPENSION MAILED
Aug 26, 2002 CNSL
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 3, 2002 CRFA
PAPER RECEIVED
Jul 3, 2002 MAIL
NON-FINAL ACTION MAILED
Dec 31, 2001 CNRT
ASSIGNED TO EXAMINER
Dec 27, 2001 DOCK